These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 30323574)

  • 1. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis.
    Filip R; Radzki RP; Bieńko M
    Clin Interv Aging; 2018; 13():1879-1891. PubMed ID: 30323574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic fatty liver disease connections with fat-free tissues: A focus on bone and skeletal muscle.
    Poggiogalle E; Donini LM; Lenzi A; Chiesa C; Pacifico L
    World J Gastroenterol; 2017 Mar; 23(10):1747-1757. PubMed ID: 28348479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone metabolism in non-alcoholic fatty liver disease: vitamin D status and bone mineral density.
    Eshraghian A
    Minerva Endocrinol; 2017 Jun; 42(2):164-172. PubMed ID: 27973461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver.
    Musso G; Paschetta E; Gambino R; Cassader M; Molinaro F
    Trends Mol Med; 2013 Sep; 19(9):522-35. PubMed ID: 23816817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications.
    Vachliotis ID; Anastasilakis AD; Goulas A; Goulis DG; Polyzos SA
    Diabetes Obes Metab; 2022 Sep; 24(9):1702-1720. PubMed ID: 35589613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Alcoholic Fatty Liver Disease and Bone Tissue Metabolism: Current Findings and Future Perspectives.
    Drapkina OM; Elkina AY; Sheptulina AF; Kiselev AR
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.
    Milić S; Lulić D; Štimac D
    World J Gastroenterol; 2014 Jul; 20(28):9330-7. PubMed ID: 25071327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology.
    Zhao J; Lei H; Wang T; Xiong X
    Front Endocrinol (Lausanne); 2023; 14():1161402. PubMed ID: 36967758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: non-alcoholic fatty liver disease and osteoporosis--clinical and molecular crosstalk.
    Yilmaz Y
    Aliment Pharmacol Ther; 2012 Aug; 36(4):345-52. PubMed ID: 22730920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
    Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
    J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAD
    Li DJ; Sun SJ; Fu JT; Ouyang SX; Zhao QJ; Su L; Ji QX; Sun DY; Zhu JH; Zhang GY; Ma JW; Lan XT; Zhao Y; Tong J; Li GQ; Shen FM; Wang P
    Theranostics; 2021; 11(9):4381-4402. PubMed ID: 33754067
    [No Abstract]   [Full Text] [Related]  

  • 13. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.
    Pacifico L; Andreoli GM; D'Avanzo M; De Mitri D; Pierimarchi P
    World J Gastroenterol; 2018 May; 24(19):2073-2082. PubMed ID: 29785076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD.
    Vacca M; Allison M; Griffin JL; Vidal-Puig A
    Semin Liver Dis; 2015 Aug; 35(3):250-61. PubMed ID: 26378642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase.
    Samala N; Tersey SA; Chalasani N; Anderson RM; Mirmira RG
    J Diabetes Complications; 2017 Nov; 31(11):1630-1637. PubMed ID: 28886991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease.
    Cimini FA; Barchetta I; Carotti S; Bertoccini L; Baroni MG; Vespasiani-Gentilucci U; Cavallo MG; Morini S
    World J Gastroenterol; 2017 May; 23(19):3407-3417. PubMed ID: 28596677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
    Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
    Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.